Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative assessment of CYB704 and Ocrevus in relapsing multiple sclerosis (STRIVE-MS)
2024-512319-40-00Phase 3Authorised
- Sponsor
- Hexal AG
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, randomised trial in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) comparing CYB704 with Ocrevus (2 arms). Primary endpoints: Primary PK endpoints, Primary PD endpoints and 3 more. Planned start Jun 2025; status: authorised.
02
Drugs
CYB704ocrelizumab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-512319-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512319-40-00.